Open an account

Myriad Genetics

MYGN · NASDAQ

$5.54+$1.33 (+31.59%)TodayMarket closed ·
Prev close $4.21

About MYGN

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company is headquartered in Salt Lake City, Utah and currently employs 2,700 full-time employees. The firm develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The firm is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. The company also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.

Employees
2,700
Headquarters
Salt Lake City, Utah
Listed
Oct 6, 1995
Sector
Health Care
Industry
Biotechnology
Website
myriad.com

MYGN key statistics

Market cap
529.90M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.75M
Volume
24.00M
Open price
$5.30
High today
$5.95
Low today
$5.25
52 Week high
$8.50
52 Week low
$2.74

Myriad Genetics (MYGN) at a glance

Myriad Genetics (MYGN) last traded at $5.54, with a market cap of 529.90M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $5.25 and $5.95. The current price is 5.5% above the day's low and 6.9% below its high.

Volume so far is 24.00M shares, above the average of 1.75M shares a day.

Over the past year Myriad Genetics has ranged from $2.74 to $8.50, and now sits 49% of the way up that range.

Myriad Genetics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.25 per share against an estimate of -$0.059.

The average analyst price target is $3.43, 38.0% below the current price, from 9 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

22%of 9 analyst ratings say Buy
  • Buy22.2%
  • Hold66.7%
  • Sell11.1%
Price target · 11 analystsAvg $3.43
Low
$2.02
Now
$5.54
High
$5.25

MYGN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 269.8% on average.

  1. Q3 FY24: reported $0.06 per share against an estimate of $0.0197
  2. Q4 FY24: reported $0.03 per share against an estimate of $0.0309
  3. Q1 FY25: reported -$0.03 per share against an estimate of -$0.0598
  4. Q2 FY25: reported $0.05 per share against an estimate of -$0.0095
  5. Q3 FY25: reported $0.00 per share against an estimate of -$0.008
  6. Q4 FY25: reported $0.04 per share against an estimate of -$0.0149
  7. Q1 FY26: reported -$0.09 per share against an estimate of -$0.0698
  8. Q2 FY26: reported -$0.25 per share against an estimate of -$0.059

MYGN news

  • Vandana Singh

    Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp

  • Avi Kapoor

    Nasdaq Rises Over 100 Points; 3M Earnings Top Views

  • Press releasePRNewswire

    SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology

  • Press releaseBusiness Wire

    MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

  • Press releasePRNewswire

    Myriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky

  • Press releaseBusiness Wire

    MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law

  • Press releaseGlobe Newswire

    MYRIAD INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Myriad Genetics, Inc. on Behalf of Myriad Stockholders and Encourages Investors to Contact the Firm

  • Press releaseGlobe Newswire

    MYRIAD GENETICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

Similar companies

Companies in the same industry as Myriad Genetics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.